NCT07270900 (L2BT2D) is a NA clinical trial of Mindfulness Based Group in Type 2 Diabetes, sponsored by Indiana University.

Who is sponsoring NCT07270900?

NCT07270900 is sponsored by Indiana University.

What drugs are being tested in NCT07270900?

Interventions in NCT07270900: Mindfulness Based Group.

What condition does NCT07270900 study?

NCT07270900 studies Type 2 Diabetes, Prediabetes.

Is NCT07270900 still recruiting?

NCT07270900 is currently completed. Last updated 8 December 2025.

Last reviewed 2025-12-08 · How we verify

NCT07270900: L2BT2D

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Mindfulness-based Intervention for Adolescents With Prediabetes or Type 2 Diabetes

Completed NA Last updated 8 December 2025

What this trial tests

NA trial testing Mindfulness Based Group in Type 2 Diabetes in 30 participants. Completed in 30 July 2025.

Timeline

1 February 2023

Primary endpoint
30 July 2024

30 July 2025

Quick facts

Lead sponsor	Indiana University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	30
Start date	1 February 2023
Primary completion	30 July 2024
Estimated completion	30 July 2025
Sites	1 location across United States

Drugs / interventions tested

Mindfulness Based Group

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Prediabetes — all drugs for Prediabetes →

Sponsor

Indiana University

Who can join

Adults 12 to 18, any sex, with Type 2 Diabetes or Prediabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to conduct a mindfulness-based intervention for adolescents referred for prediabetes or type 2 diabetes treatment to 1) evaluate feasibility and acceptability of the intervention for future research and clinical use and 2) explore secondary health outcomes related to diabetes prevention and care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Learning to Breathe with Type 2 Diabetes: A Pilot Feasibility and Acceptability Study of a Mindfulness-Based Intervention in Youth with Type 2 Diabetes or Prediabetes.
Pike JM, Yorgason J, Machuca LA, Broderick PC, et al · · 2026 · PMID 42163895 · DOI 10.2337/doc25-0047

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07270900 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 8 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07270900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing